According to the Zhitong Finance App, Joint Medical (00722) issued an announcement. The board of directors recommended the adoption of the 2023 share option plan. The provisions of the plan will comply with the provisions of Chapter 17 of the revised listing rules. The 2023 share option plan will be valid for ten years from the date of adoption.
The 2023 share option plan aims to replace the post-IPO share option plan and enable the company to grant share options to selected eligible persons as a reward or reward for their contribution or potential contribution to the Group's development and long-term growth, to help the Group recruit and retain high-quality professionals, executives and employees who play an important role in the Group's growth and development.